Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US-9458112-B2 · Oct 4, 2016 · US
Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
US9896475B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9896475-B2 |
| Application number | US-201515505327-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 26, 2015 |
| Priority date | Aug 26, 2014 |
| Publication date | Feb 20, 2018 |
| Grant date | Feb 20, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl) imidazole and pharmaceutical compositions containing the same are provided. The present invention is a tnterpenoid compound of Formula I, or a hydrate, isomer, prodrug or pharmaceutically acceptable salt thereof: wherein one or more of R, R or R is independently a substituted or unsubstituted aryl group, heteroaryl group, cycloalkyl group or heterocyclyl group, and the remaining R groups are hydrogen. The pyridyl analogs of CD-DO-1m 1 have been developed, which are more stable in human plasma and achieve a higher concentration in target tissues such as liver, pancreas, kidney and lungs.
First claim
Opening claim text (preview).
What is claimed is: 1. A triterpenoid compound having the structure of Formula I, or a hydrate, isomer, prodrug or pharmaceutically acceptable salt thereof: wherein one or more of R 1 , R 2 or R 3 is independently a substituted or unsubstituted heteroaryl group, cycloalkyl group or heterocyclyl group, and the remaining R groups are hydrogen. 2. The triterpenoid compound of claim 1 , wherein R 2 is a substituted or unsubstituted heteroaryl group, cycloalkyl group or heterocyclyl group, and R 1 and R 3 are hydrogen. 3. A pharmaceutical composition comprising the compound of claim 1 in admixture with a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
- C07D233/54Primary
having two double bonds between ring members or between ring members and non-ring members · CPC title
- C07J61/00Primary
Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9896475B2 cover?
- Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl) imidazole and pharmaceutical compositions containing the same are provided. The present invention is a tnterpenoid compound of Formula I, or a hydrate, isomer, prodrug or pharmaceutically acceptable salt thereof: wherein one or more of R, R or R is independently a substituted or unsubstituted aryl group, heteroaryl group, cyclo…
- Who is the assignee on this patent?
- Dartmouth College
- What technology area does this patent fall under?
- Primary CPC classification C07D233/54. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).